Hussman Strategic Advisors Inc. Grows Position in AxoGen, Inc. (NASDAQ:AXGN)

Hussman Strategic Advisors Inc. increased its position in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 100.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 63,000 shares of the medical equipment provider's stock after acquiring an additional 31,500 shares during the period. Hussman Strategic Advisors Inc. owned about 0.14% of AxoGen worth $1,166,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Driehaus Capital Management LLC increased its position in shares of AxoGen by 166.0% during the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider's stock worth $15,729,000 after acquiring an additional 595,579 shares during the period. First Light Asset Management LLC grew its position in shares of AxoGen by 10.2% in the 4th quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider's stock valued at $74,272,000 after buying an additional 416,499 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of AxoGen during the fourth quarter worth about $4,943,000. Raymond James Financial Inc. acquired a new stake in shares of AxoGen in the fourth quarter valued at about $4,552,000. Finally, Assenagon Asset Management S.A. grew its holdings in shares of AxoGen by 21.1% during the first quarter. Assenagon Asset Management S.A. now owns 1,001,217 shares of the medical equipment provider's stock worth $18,523,000 after buying an additional 174,681 shares in the last quarter. Institutional investors own 80.29% of the company's stock.

AxoGen Trading Down 3.0%

AXGN stock traded down $0.35 during mid-day trading on Friday, reaching $11.28. The company's stock had a trading volume of 676,057 shares, compared to its average volume of 518,928. The company has a market cap of $513.69 million, a price-to-earnings ratio of -75.19 and a beta of 1.04. AxoGen, Inc. has a 12 month low of $7.34 and a 12 month high of $21.00. The business's 50 day moving average price is $10.92 and its 200 day moving average price is $15.11. The company has a current ratio of 4.28, a quick ratio of 2.65 and a debt-to-equity ratio of 0.63.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reduced their price objective on shares of AxoGen from $26.00 to $24.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AxoGen currently has a consensus rating of "Buy" and a consensus price target of $24.50.

Insider Activity

In other AxoGen news, Director Joseph A. Tyndall sold 20,062 shares of the business's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $11.20, for a total value of $224,694.40. Following the transaction, the director owned 15,345 shares of the company's stock, valued at approximately $171,864. The trade was a 56.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.78% of the stock is currently owned by insiders.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.